Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
C 7.04 -6.01% -0.45
FATE closed down 6.01 percent on Monday, March 18, 2024, on 76 percent of normal volume.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Crossed Above 20 DMA Bullish -6.01%
Pocket Pivot Bullish Swing Setup -6.01%
Volume Surge Other -6.01%
Bollinger Band Squeeze Range Contraction -6.01%
NR7 Range Contraction -6.01%
Fell Below 20 DMA Bearish -2.63%
Bollinger Band Squeeze Range Contraction -2.63%
BB Squeeze Started Range Contraction -2.63%

   Recent Intraday Alerts

Alert Time
Down 5% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Down 3% about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fate Therapeutics, Inc. Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Stem Cell Hematologic Malignancies Hematopoietic Stem Cell Induced Stem Cells Orphan Disease Adult Stem Cell Blood Cells Cord Blood Lysosomal Storage Disorder Lysosomal Storage Disorders Muscular Dystrophies Umbilical Cord

Is FATE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.83
52 Week Low 1.63
Average Volume 2,987,196
200-Day Moving Average 3.94
50-Day Moving Average 6.19
20-Day Moving Average 7.38
10-Day Moving Average 7.63
Average True Range 0.69
RSI (14) 50.00
ADX 48.78
+DI 24.75
-DI 16.45
Chandelier Exit (Long, 3 ATRs) 6.77
Chandelier Exit (Short, 3 ATRs) 8.52
Upper Bollinger Bands 8.27
Lower Bollinger Band 6.48
Percent B (%b) 0.31
BandWidth 24.22
MACD Line 0.36
MACD Signal Line 0.50
MACD Histogram -0.1362
Fundamentals Value
Market Cap 694.16 Million
Num Shares 98.6 Million
EPS -1.77
Price-to-Earnings (P/E) Ratio -3.98
Price-to-Sales 5.84
Price-to-Book 1.54
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.87
Resistance 3 (R3) 7.93 7.71 7.73
Resistance 2 (R2) 7.71 7.50 7.68 7.68
Resistance 1 (R1) 7.38 7.37 7.27 7.32 7.64
Pivot Point 7.16 7.16 7.11 7.13 7.16
Support 1 (S1) 6.83 6.95 6.72 6.77 6.44
Support 2 (S2) 6.61 6.82 6.58 6.40
Support 3 (S3) 6.28 6.61 6.35
Support 4 (S4) 6.22